Acorda Therapeutics, Inc. (NASDAQ:ACOR – Get Rating) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.54 and traded as high as $1.00. Acorda Therapeutics shares last traded at $0.98, with a volume of 322,644 shares traded.
Analyst Ratings Changes
Separately, StockNews.com raised shares of Acorda Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, January 13th.
Acorda Therapeutics Price Performance
The company has a debt-to-equity ratio of 2.48, a quick ratio of 1.34 and a current ratio of 1.71. The company has a market cap of $23.67 million, a PE ratio of -0.14 and a beta of 1.41. The company’s 50-day simple moving average is $0.68 and its 200 day simple moving average is $0.54.
Hedge Funds Weigh In On Acorda Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Prudential Financial Inc. purchased a new position in Acorda Therapeutics in the 2nd quarter valued at approximately $28,000. Virtu Financial LLC purchased a new stake in shares of Acorda Therapeutics during the 2nd quarter worth $68,000. Millennium Management LLC lifted its position in shares of Acorda Therapeutics by 661.2% during the 2nd quarter. Millennium Management LLC now owns 311,509 shares of the biopharmaceutical company’s stock worth $145,000 after purchasing an additional 270,588 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Acorda Therapeutics by 27.4% during the 2nd quarter. Renaissance Technologies LLC now owns 901,318 shares of the biopharmaceutical company’s stock worth $420,000 after purchasing an additional 194,100 shares during the last quarter. Hedge funds and other institutional investors own 25.86% of the company’s stock.
About Acorda Therapeutics
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.
- Get a free copy of the StockNews.com research report on Acorda Therapeutics (ACOR)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.